Negatively charged liposomes of sertraline hydrochloride: Formulation, characterization and pharmacokinetic studies

Chauhan, Tejpratap; Rani, Varsha; Sahu, Bhupendra; Sharma, Adity; Kheruka, Subhash Chand; Gambhir, Sanjay; Dube, Veeresh; Aggarwal, Lalit Mohan; Chawla, Ruchi

doi:10.1016/j.jddst.2020.101780

Cited by 5 publications

(2 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As with other NPs, RES clearance is another important aspect to be looked into in the application of liposomes as DDS. There are several studies showing the importance of vesicle size, lipid composition, surface coating, surface charges, and liposomes–plasma protein interaction on the clearance of liposomes by the RES [ 79 , 80 , 81 , 82 ]. Hence, selecting suitable lipids, increasing the vesicle stability by adding cholesterol and coating the liposome with polymers (which will produce stealth liposomes) are the approaches that may improve the circulation time of liposomes in blood [ 83 ].…”

Section: Drug Delivery For DCXmentioning

confidence: 99%

Advances in Nanocarriers for Effective Delivery of Docetaxel in the Treatment of Lung Cancer: An Overview

Razak

Gazzali

Fisol

et al. 2021

Cancers

View full text Add to dashboard Cite

Docetaxel (DCX) is a highly effective chemotherapeutic drug used in the treatment of different types of cancer, including non-small cell lung cancer (NSCLC). The drug is known to have low oral bioavailability due to its low aqueous solubility, poor membrane permeability and susceptibility to hepatic first-pass metabolism. To mitigate these problems, DCX is administered via the intravenous route. Currently, DCX is commercially available as a single vial that contains polysorbate 80 and ethanol to solubilize the poorly soluble drug. However, this formulation causes short- and long-term side effects, including hypersensitivity, febrile neutropenia, fatigue, fluid retention, and peripheral neuropathy. DCX is also a substrate to the drug efflux pump P-glycoprotein (P-gp) that would reduce its concentration within the vicinity of the cells and lead to the development of drug resistance. Hence, the incorporation of DCX into various nanocarrier systems has garnered a significant amount of attention in recent years to overcome these drawbacks. The surfaces of these drug-delivery systems indeed can be functionalized by modification with different ligands for smart targeting towards cancerous cells. This article provides an overview of the latest nanotechnological approaches and the delivery systems that were developed for passive and active delivery of DCX via different routes of administration for the treatment of lung cancer.

show abstract

Section: Drug Delivery For DCXmentioning

confidence: 99%

Advances in Nanocarriers for Effective Delivery of Docetaxel in the Treatment of Lung Cancer: An Overview

Razak

Gazzali

Fisol

et al. 2021

Cancers

View full text Add to dashboard Cite

show abstract

“…Moreover, liposomes are produced with greater physicochemical property control and reproducibility, making these methods suitable for industrial production under GMP (Good manufacturing practice) guidelines. In addition, due to the properties of SCF, the use of organic solvents can be controlled or eliminated [6,24]. SCF can be used as an antisolvent in the SAS (Supercritical antisolvent), ASES (Aerosol solvent extraction system), or GAS (Gas Antisolvent) processes, in which an organic solvent is utilized to solubilize lipids, which are subsequently precipitated by the antisolvent effect of SCF.…”

Section: Introductionmentioning

confidence: 99%

Preparation Irinotecan Hydrochloride Loaded PEGylated Liposomes Using Novel Method Supercritical Fluid and Condition Optimized by Box-Behnken Design

Mohammadi,

Karimi,

Raofie

2024

Preprint

View full text Add to dashboard Cite

A semi-synthetic camptothecin derivative known as irinotecan hydrochloride is frequently used to treat colorectal cancer (CRC), including colorectal adenocarcinoma and lung cancers involving small cells. Irinotecan has a very short half-life; therefore, continuous infusions are required to keep the drug's blood levels at therapeutic levels, which could produce cumulative toxicities. Effective delivery techniques, including liposomes, have been developed to address these shortcomings. In this study, a continuous supercritical fluid approach dubbed Expansion Supercritical Fluid into an aqueous solution (ESSAS), in which the pressure decreases rapidly but remains over the critical pressure, is proposed to manufacture polyethylene glycolylated (PEGylated) liposomes carrying irinotecan hydrochloride. To accomplish this, PEGylated liposomes were created using a Box-Behnken design, and the operating parameters (flow rate, temperature, and pressure drop) were optimized. Encapsulation efficiency, mean size, and prepared liposome count were 94.6%, 55 nm, and 758 under ideal circumstances. Additionally, the stability of the PEGylated liposome was investigated during 8 weeks, and also PEGylated liposome-loaded irinotecan release profile was compared to conventional liposomes and free irinotecan, and a constant drug release was seen after the first burst release from liposomes.

show abstract

Development of Liposomal Formulation for Controlled Delivery of Valacyclovir: an In Vitro Study

et al. 2023

View full text Add to dashboard Cite

Negatively charged liposomes of sertraline hydrochloride: Formulation, characterization and pharmacokinetic studies

Cited by 5 publications

References 17 publications

Advances in Nanocarriers for Effective Delivery of Docetaxel in the Treatment of Lung Cancer: An Overview

Advances in Nanocarriers for Effective Delivery of Docetaxel in the Treatment of Lung Cancer: An Overview

Preparation Irinotecan Hydrochloride Loaded PEGylated Liposomes Using Novel Method Supercritical Fluid and Condition Optimized by Box-Behnken Design

Development of Liposomal Formulation for Controlled Delivery of Valacyclovir: an In Vitro Study

Contact Info

Product

Resources

About